uniQure (QURE) SEC Filings: History & Chart

uniQure N.V.(QURE)

Biotechnology · Amsterdam, NH

$23.06+0.26 (+1.14%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Amsterdam, NH

221 employees

www.uniqure.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Matthew C. Kapusta

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 29, 2026	Sep 29, 2026	View filing
8-K	Sep 2, 2026	Sep 2, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G	Aug 14, 2026	Aug 14, 2026	View filing
S-8	Jul 29, 2026	Jul 29, 2026	View filing
10-Q	Jul 29, 2026	Jul 29, 2026	View filing
8-K	Jul 29, 2026	Jul 29, 2026	View filing
SC 13G/A	Jul 20, 2026	Jul 20, 2026	View filing
SC 13G	Jul 16, 2026	Jul 16, 2026	View filing
4	Jul 7, 2026	Jul 7, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jun 30, 2026	Jun 30, 2026	View filing
4	Jun 26, 2026	Jun 26, 2026	View filing
8-K	Jun 24, 2026	Jun 24, 2026	View filing
424B5	Jun 24, 2026	Jun 24, 2026	View filing
424B5	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
8-K	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 17, 2026	Jun 17, 2026	View filing
4	Jun 17, 2026	Jun 17, 2026	View filing
8-K	Jun 17, 2026	Jun 17, 2026	View filing
8-K	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing

SEC Filings

Recent Filings